Combination therapy of acetylcholinesterase inhibitor and vitamin e in Alzheimer disease

Journal of Clinical Psychopharmacology

Volumn 29, Issue 5, 2009, Pages 511-513

  Bittner, Daniel M ^a,b  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; APOLIPOPROTEIN E; DONEPEZIL; GALANTAMINE; RIVASTIGMINE;

ALZHEIMER DISEASE; COGNITION; COMBINATION CHEMOTHERAPY; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; GENOTYPE; HUMAN; LETTER; MINI MENTAL STATE EXAMINATION; MONOTHERAPY; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

AGED; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VITAMIN E;

EID: 70349682141     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181b54961     Document Type: Letter

References (16)

1. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol or both as treatment for Alzheimer's disease. N Engl J Med. 1997;336:1216-1222.
2. Halliwell B, Gutteridge JMC. Oxygen radicals in the neuron system. Trends Neurosci. 1985;8:22-26.
3. Corey-Bloom J, Anand R, Veach J, et al. A randomized trial evaluating the efficacy and safety of ENA713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol. 1998;1:55-65.
4. Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6 month extension. The Galantamine USA-1 Study Group. Neurology. 2000;54:2261-2268.
5. Rogers SL, Doody RS, Pratt RD. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicenter open-label study. Eur Neuropsychopharmacol. 2000;10:195-203.
6. Rogers SL, Farlow MD, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology. 1998;50:136-145.
7. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomized controlled trial. BMJ. 1999; 318:633-638.
8. Klatte ET, Scharre DW, Nagaraja HN, et al. Combination therapy of donepezil and vitamin E in Alzheimer's disease. Alzheimer Dis Assoc Disord. 2003;17:113-116.
9. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDAWork Group under auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
10. Hackler R, Schafer JR, Motzny S, et al. Rapid determination of apolipoprotein E phenotypes from whole plasma by automated isoelectric focusing using PhastSystem and immunofixation. J Lipid Res. 1994;35: 153-158.
11. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
12. Milatovic D, Gupta RC, Aschner M. Anticholinesterase toxicity and oxidative stress. ScientificWorldJournal. 2006;6:295-310.
13. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303-308.
14. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2006;352:2379-2388.
15. Jack CR Jr, Petersen RC, Grundman M, et al. Longitudinal findings from the vitamin E and donepezil treatment study for MCI. Neurobiol Aging. 2008;29:1285-1295.
16. Miller ER III, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142:37-46.